[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100646423":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":31,"collaborators":24,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":24,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":24,"enrollmentInfo":42,"targetDuration":24,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":24,"overallStatus":51,"whyStopped":24,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":24},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Fosrolapitant and Palonosetron + dexamethasone + placebo","EXPERIMENTAL","Use this field to provide additional information about the arm, including a description of the intervention(s) administered.",[13],"Drug: Fosrolapitant and Palonosetron for injection",{"label":15,"type":16,"description":11,"interventionNames":17},"fosaprepitant dimeglumine for injection+palonosetron hydrochloride injection+dexamethasone","ACTIVE_COMPARATOR",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Fosrolapitant and Palonosetron for injection","• Experimental: Drug：Fosrolapitant and Palonosetron for injection Drug：Dexamethasone Drug: placebo\n\n• Active Comparator: Drug：HR20013 placebo Drug: fosaprepitant dimeglumine for injection Drug：Palonosetron injection Drug: Dexamethasone",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"li huiping chief physician","CONTACT","+86-13811012595","huipingli2012@hotmail.com",{"type":32,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100646423","phase-2-fosrolapitant-and-palonosetron-for-the-prevention-of-antibody-drug-conjugate-induced-nausea-and-vomiting-100646423",false,"NCT07692451","Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting","A Randomized Controlled Study of Fosrolapitant and Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugates in Cancer Patients","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n1. 18 years of age or older, of either gender\n2. Has a diagnosed malignant tumor\n3. has never been treated with ADCs and is to receive the first course of ADCs\n4. Predicted life expectancy of ≥ 3 months\n5. Has a performance status (ECOG scale) of 0 to 1\n6. Adequate bone marrow, kidney, and liver function\n7. Women of childbearing potential must have negative pregnancy test (serum test) results within 72 hours prior to enrollment\n8. Able and willing to provide a written informed consent","ALL","18 Years",{"count":43,"type":44},124,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting",[50],"Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)","NOT_YET_RECRUITING","2026-07-03",{"date":54,"type":55},"2026-07-09","ACTUAL",{"date":57,"type":44},"2026-07-15",{"date":59,"type":44},"2027-09-30",{"name":5,"class":6}]